Patents by Inventor Anne Petit

Anne Petit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition containing a somatostatin analogue for radiopharmaceutical use
    Patent number: 11969484
    Abstract: The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: April 30, 2024
    Assignee: Ariceum Therapeutics GmbH
    Inventors: Marie Delporte, Sabine Hovest, Jens Kaufmann, Dennis Mewis, Anne Petit, Joel Richard
  • Composition Containing a Somatostatin Analogue for Radiopharmaceutical Use
    Publication number: 20230181771
    Abstract: The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.
    Type: Application
    Filed: June 20, 2019
    Publication date: June 15, 2023
    Inventors: Marie Delporte, Sabine Hovest, Jens Kaufmann, Dennis Mewis, Anne Petit, Joel Richard
  • Composition Containing a Somatostatin Analogue for Radiopharmaceutical Use
    Publication number: 20210128758
    Abstract: The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.
    Type: Application
    Filed: June 20, 2019
    Publication date: May 6, 2021
    Inventors: Romain Bejot, Bilal Karaaouil, Didier Kubiak, Anne-Claire Le Meur, Didier Nourrisson, Anne Petit, Joel Richard, Camille Toulisse
  • Contrast medium formulation and related preparation method
    Patent number: 10918743
    Abstract: The present invention relates to a liquid pharmaceutical composition including a complex of formula (I), in which M is an ion of a paramagnetic metal and R1 to R3, X1 to X3 and K1 to K12 are such as defined in claim 1, said composition also including a calcium complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The invention also relates to the preparation method thereof and to an imaging method involving said composition.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: February 16, 2021
    Assignee: GUERBET
    Inventors: Christelle Medina, Monique Sabatou, Anne Petit, Marc Port
  • Pharmaceutical composition for a sustained release of lanreotide
    Patent number: 10543249
    Abstract: A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 28, 2020
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Ruth Bielsa Guivernau, Roland Cherif-Cheikh, Julie Fournes, Daniel Martinez Lorente, Anne Petit, Joël Richard
  • AQUEOUS SUSTAINED RELEASE COMPOSITIONS OF LHRH ANALOGUES
    Publication number: 20160184386
    Abstract: An aqueous pharmaceutical composition for the sustained release of an LHRH analogue, in particular for a sustained release compatible with therapeutic treatments for at least 2 weeks. The pharmaceutical compositions are particularly useful for the treatment of diseases an LHRH analogue is indicated for.
    Type: Application
    Filed: July 21, 2014
    Publication date: June 30, 2016
    Inventors: Joel RICHARD, Anne PETIT, Jeremiah HARNETT, Marie-Madeleine BARONNET, Franck ARTZNER, Mercedes CARDUS MALESPINA, Roland CHERIF-CHEIKH, Martin MONTES, Marie-Therese PATERNOSTRE, Celine VALERY
  • PHARMACEUTICAL COMPOSITION FOR A SUSTAINED RELEASE OF LANREOTIDE
    Publication number: 20160151447
    Abstract: A pharmaceutical composition for a sustained release of peptide therapeutics, in particular for a sustained release compatible with therapeutic treatments of at least two months. In an embodiment, the composition comprises lanreotide as an active agent, a hydrosoluble co-solvent, and water with the pH of the composition being from 4.0 to 7.5.
    Type: Application
    Filed: July 8, 2014
    Publication date: June 2, 2016
    Inventors: Ruth BIELSA GUIVERNAU, Roland CHERIF-CHEIKH, Julie FOURNES, Daniel MARTINEZ LORENTE, Anne PETIT, Joël RICHARD
  • CONTRAST MEDIUM FORMULATION AND RELATED PREPARATION METHOD
    Publication number: 20160101196
    Abstract: The present invention relates to a liquid pharmaceutical composition including a complex of formula (I), in which M is an ion of a paramagnetic metal and R1 to R3, X1 to X3 and K1 to K12 are such as defined in claim 1, said composition also including a calcium complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. The invention also relates to the preparation method thereof and to an imaging method involving said composition.
    Type: Application
    Filed: April 28, 2014
    Publication date: April 14, 2016
    Applicant: GUERBET
    Inventors: Christelle Medina, Monique Sabatou, Anne Petit, Marc Port
  • Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions
    Publication number: 20150239959
    Abstract: Antibodies and antigen-binding molecules directed against Hepatitis C virus (HCV) are presented. The antibodies and antigen-binding molecules specifically bind to the HCV E1E2 complex. Also provided are pharmaceutical compositions containing the antibodies and/or antigen-binding molecules. Nucleic acids encoding the antibodies and antigen-binding molecules, along with corresponding expression vectors and host cells are also provided.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Inventors: Marie Anne PETIT, Emmanuel DROUET, Christian TREPO
  • Antibodies Directed Against Hepatitis C Virus E1E2 Complex, Compositions of HCV Particles, and Pharmaceutical Compositions
    Publication number: 20130052187
    Abstract: New conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well as processes for their preparation.
    Type: Application
    Filed: September 14, 2012
    Publication date: February 28, 2013
    Applicants: INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Universite Joseph Fourier (Grenoble), BIOMERIEUX SA
    Inventors: Marie Anne PETIT, Emmanuel DROUET, Christian TREPO
  • ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS E1E2 COMPLEX, COMPOSITIONS OF HCV PARTICLES, AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110311551
    Abstract: The invention provides new conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, that are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well as processes for their preparation.
    Type: Application
    Filed: May 24, 2011
    Publication date: December 22, 2011
    Inventors: Marie Anne PETIT, Emmanuel DROUET, Christian TREPO
  • Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions
    Patent number: 8007792
    Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: August 30, 2011
    Assignees: INSERM, Biomerieux SA
    Inventors: Marie-Anne Petit, Colette Jolivet-Reynaud, Christian Trepo
  • ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS E1E2 COMPLEX, COMPOSITIONS OF HCV PARTICLES, AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20090186023
    Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.
    Type: Application
    Filed: March 20, 2009
    Publication date: July 23, 2009
    Inventors: Marie-Anne Petit, Colette Jolivet-Raynaud
  • Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions
    Patent number: 7524650
    Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: April 28, 2009
    Assignees: INSERM, Biomerieux SA
    Inventors: Marie-Anne Petit, Colette Jolivet-Reynaud
  • Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
    Publication number: 20070026003
    Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.
    Type: Application
    Filed: March 31, 2004
    Publication date: February 1, 2007
    Inventors: Marie-Anne Petit, Colette Jolivet-Reynaud